PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.62%
Positive net income growth while Biotechnology median is negative at -4.09%. Peter Lynch would view it as a strong advantage vs. struggling peers.
3.20%
D&A growth under 50% of Biotechnology median of 0.02%, or significantly exceeding it. Jim Chanos would suspect overcapacity or misallocated capex if new assets do not pay off quickly.
No Data
No Data available this quarter, please select a different quarter.
22.07%
SBC growth of 22.07% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
81.65%
Working capital of 81.65% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.82%
AP growth of 50.82% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
28.44%
Growth of 28.44% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-17.77%
Other non-cash items dropping yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
18.75%
CFO growth of 18.75% while Biotechnology median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
-1425.00%
CapEx declines yoy while Biotechnology median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1425.00%
Reduced investing yoy while Biotechnology median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.